Leishmaniasis control in the light of the COVID-19 pandemic in Africa

Leishmaniasis is a parasitic disease, endemic to Africa, Asia, and South America due to inadequate access to medication and underreporting of leishmaniasis cases. Leishmaniasis has two forms: cutaneous and visceral. The fight against leishmaniasis has been greatly affected by the coronavirus disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Uwishema, Olivier, Sapkota, Suhail, Wellington, Jack, Onyeaka, Chinyere Vivian Patrick, Onyeaka, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339101/
https://www.ncbi.nlm.nih.gov/pubmed/35936565
http://dx.doi.org/10.1016/j.amsu.2022.104263
Descripción
Sumario:Leishmaniasis is a parasitic disease, endemic to Africa, Asia, and South America due to inadequate access to medication and underreporting of leishmaniasis cases. Leishmaniasis has two forms: cutaneous and visceral. The fight against leishmaniasis has been greatly affected by the coronavirus disease 2019 (COVID-19) pandemic that impacted resource distribution and access to medication. Continuous effort in vaccine development and affordable therapeutics are necessary to eliminate leishmaniasis in low-income countries. Further research is necessary to determine molecular drug resistance markers in leishmaniasis patients. In this analysis, we focus on the effect of COVID-19 on leishmaniasis in Africa.

Ejemplares similares